JPM 2026: Aurora Therapeutics’ Edward Kaye on Scalable Personalized Gene Editing
Previous
Previous
Biotech CEOs discuss the state of the industry, what is needed to compete globally, the importance of having a patient-centric approach, and more
Next
Next